Home

PRI2 (human)

Overview PRI2 synthesizes small RNA primers for the Okazaki fragments made during discontinuous DNA replication. The replication of DNA is carried out by a complex chromosomal replication apparatus, in which DNA polymerase alpha and primase are two key enzymatic components. Note: This description may include information from UniProtKB. Protein type: Transferase; EC 2.7.7.-; Nucleotide Metabolism - pyrimidine; Nucleotide Metabolism - purine Cellular Component: nucleoplasm; alpha DNA polymerase:primase complex Molecular Function: DNA primase activity; DNA binding; metal ion binding; 4 iron, 4 sulfur cluster binding Biological Process: telomere maintenance via semi-conservative replication; DNA replication initiation; M/G1 transition of mitotic cell cycle; telomere maintenance via recombination; DNA replication, synthesis of RNA primer; mitotic cell cycle; DNA strand elongation during DNA replication; S phase of mitotic cell cycle; telomere maintenance; G1/S transition of mitotic cell cycle Reference #:  P49643 (UniProtKB) Alt. Names/Synonyms: dJ422B11.1.1; DNA primase 58 kDa subunit; DNA primase large subunit; DNA primase polypeptide 2; DNA primase subunit p58; MGC75142; p58; polypeptide 2A, p58; PRI2; PRIM2; PRIM2A; primase polypeptide 2A, 58kDa; primase, DNA, polypeptide 2 (58kDa); primase, polypeptide 2A (58kD) Gene Symbols: PRIM2 Molecular weight: 58,806 Da Basal Isoelectric point: 7.97  Predict pI for various phosphorylation states Protein-Specific Antibodies or siRNAs from Cell Signaling Technology®

Select Structure to View Below PRI2 3L9Q - A/B=272-464 (human) 3Q36 - A/B=266-457 (human)

STRING  |  Scansite  |  Phospho.ELM  |  NetworKIN  |  Pfam  |  RCSB PDB 3L9Q 3Q36  |  ENZYME  |  Phospho3D  |  DISEASE  |  Source  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene

	Modification Sites and Domains	Show Modification Legend
Click here to view phosphorylation modifications only

	Modification Sites in Parent Protein, Orthologs, and Isoforms	Show Modification Legend

SS  SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.	MS  MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.			human
0	1		S4-p	____MEFsGRKWRKL
0	1		K54-u	IDRVKLLksVENLGV
0	1		S55-p	DRVKLLksVENLGVs
0	1		S62-p	sVENLGVsyVkGTEQ
0	1		Y63-p	VENLGVsyVkGTEQY
0	1		K65-u	NLGVsyVkGTEQYQS
0	1		K73-u	GTEQYQSkLESELRK
0	1		K139-u	FSILPKDkIQDFLkD
0	1		K145-u	DkIQDFLkDSQLQFE
0	1		S155	QLQFEAISDEEkTLR
0	1		K159-u	EAISDEEkTLREQEI
0	1		K177-u	SPSLSGLkLGFESIY
0	3		Y201-p	LFRGRKVyLEDGFAy
0	2		Y208-p	yLEDGFAyVPLKDIV
0	1		S377-p	IILSNPPsQGDyHGC
0	78		Y381-p	NPPsQGDyHGCPFRH
0	1		Y401-p	LKQKLQSykISPGGI
0	1		K402-u	KQKLQSykISPGGIS
0	13		T470-p	KEPIQPEtPQPkPSV
0	1		K474-a	QPEtPQPkPSVQKTK
0	1		S485-p	QKTKDASsALAsLNs
0	1		S489-p	DASsALAsLNsSLEM
0	1		S492-p	sALAsLNsSLEMDME

	mouse
S4	____MQFSGRIRKKL
K54	FDRVKLLKAIENLGV
A55	DRVKLLKAIENLGVS
S62	AIENLGVSYVKGTEQ
Y63	IENLGVSYVKGTEQY
K65	NLGVSYVKGTEQYQS
K73	GTEQYQSKLEAEIRK
K139	FSILPKDKVQSFLKD
K145	DKVQSFLKDSHLHFE
S155-p	HLHFEAIsDEEKTLR
K159	EAIsDEEKTLREQDI
K177	SPSLSGIKLESESVY
Y201	LFRGRKVYLEDGFAY
Y208	YLEDGFAYVPLKDIV
G377	IILTNPPGQGDyHGC
Y381-p	NPPGQGDyHGCPFRH
Y401	LKQKMQSYKIPASGI
K402	KQKMQSYKIPASGIS
T470	KEISQPETPQHKPST
K474	QPETPQHKPSTQKTR
S485	QKTRDAASALASLDS
S489	DAASALASLDSSLEM
S492	SALASLDSSLEMDLE

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E Produced by 3rd Millennium  |  Design by Digizyme ©2003-2013 Cell Signaling Technology, Inc.